• Je něco špatně v tomto záznamu ?

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study

DP. Zipes, P. Neuzil, H. Theres, D. Caraway, DL. Mann, C. Mannheimer, P. Van Buren, C. Linde, B. Linderoth, F. Kueffer, SA. Sarazin, MJ. DeJongste, . ,

. 2016 ; 4 (2) : 129-36. [pub] 20151209

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000759

OBJECTIVES: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. BACKGROUND: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. METHODS: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35%, QRS duration <120 ms, and left ventricular end-diastolic dimension ≥55 mm. The primary objective of the DEFEAT-HF study was to evaluate the reduction in LVESVi after 6 months of SCS therapy in the treatment arm compared to the control arm. RESULTS: In total, 81 patients were enrolled, with 66 successfully randomized and implanted with the SCS device system. Seventy-six percent (50 of 66) had an implantable cardioverter-defibrillator at the baseline visit. Among randomized patients, the mean age was 61 years, 79% were male, mean LVEF was 27%, and mean QRS duration was 105 ms. The change in LVESVi over 6 months was not significantly different between randomization arms (SCS OFF: -2.2 [95% confidence interval: -9.1 to 4.6] vs. SCS ON: 2.1 [95% confidence interval: -2.7 to 6.9]; p = 0.30). Analyses of secondary endpoints for the study were also not significantly different. CONCLUSIONS: The present study does not provide evidence to support a meaningful change in clinical outcomes for HF patients receiving SCS. (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure [DEFEAT-HF]; NCT01112579).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000759
003      
CZ-PrNML
005      
20170118121158.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jchf.2015.10.006 $2 doi
024    7_
$a 10.1016/j.jchf.2015.10.006 $2 doi
035    __
$a (PubMed)26682789
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zipes, Douglas P $u Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: dzipes@iu.edu.
245    10
$a Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study / $c DP. Zipes, P. Neuzil, H. Theres, D. Caraway, DL. Mann, C. Mannheimer, P. Van Buren, C. Linde, B. Linderoth, F. Kueffer, SA. Sarazin, MJ. DeJongste, . ,
520    9_
$a OBJECTIVES: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. BACKGROUND: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. METHODS: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35%, QRS duration <120 ms, and left ventricular end-diastolic dimension ≥55 mm. The primary objective of the DEFEAT-HF study was to evaluate the reduction in LVESVi after 6 months of SCS therapy in the treatment arm compared to the control arm. RESULTS: In total, 81 patients were enrolled, with 66 successfully randomized and implanted with the SCS device system. Seventy-six percent (50 of 66) had an implantable cardioverter-defibrillator at the baseline visit. Among randomized patients, the mean age was 61 years, 79% were male, mean LVEF was 27%, and mean QRS duration was 105 ms. The change in LVESVi over 6 months was not significantly different between randomization arms (SCS OFF: -2.2 [95% confidence interval: -9.1 to 4.6] vs. SCS ON: 2.1 [95% confidence interval: -2.7 to 6.9]; p = 0.30). Analyses of secondary endpoints for the study were also not significantly different. CONCLUSIONS: The present study does not provide evidence to support a meaningful change in clinical outcomes for HF patients receiving SCS. (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure [DEFEAT-HF]; NCT01112579).
650    _2
$a senioři $7 D000368
650    _2
$a design vybavení $7 D004867
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a systolické srdeční selhání $x terapie $7 D054143
650    _2
$a lidé $7 D006801
650    12
$a implantabilní neurostimulátory $7 D058542
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a jednoduchá slepá metoda $7 D016037
650    _2
$a míšní stimulace $x přístrojové vybavení $7 D062187
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Neuzil, Petr $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Theres, Heinz $u Charité Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Caraway, David $u St. Mary's Medical Center, Huntington, West Virginia.
700    1_
$a Mann, Douglas L $u Washington University School of Medicine, St. Louis, Missouri.
700    1_
$a Mannheimer, Clas $u Sahlgrenska University Hospital, Göteborg, Sweden.
700    1_
$a Van Buren, Peter $u Fletcher Allen Healthcare, Burlington, Vermont.
700    1_
$a Linde, Cecilia $u Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Linderoth, Bengt $u Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Kueffer, Fred $u Medtronic, Minneapolis, Minnesota.
700    1_
$a Sarazin, Scott A $u Medtronic, Minneapolis, Minnesota.
700    1_
$a DeJongste, Michael J L $u Universitair Medisch Centrum Groningen and University of Groningen, Groningen, the Netherlands.
700    1_
$a ,
773    0_
$w MED00184931 $t JACC. Heart failure $x 2213-1787 $g Roč. 4, č. 2 (2016), s. 129-36
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26682789 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170118121305 $b ABA008
999    __
$a ok $b bmc $g 1179899 $s 961326
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 4 $c 2 $d 129-36 $e 20151209 $i 2213-1787 $m JACC. Heart failure $n JACC Heart Fail $x MED00184931
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace